MALCOLM BRENNER to Transgenes
This is a "connection" page, showing publications MALCOLM BRENNER has written about Transgenes.
Connection Strength
1.963
-
Adoptive T cell therapy of cancer. Curr Opin Immunol. 2010 Apr; 22(2):251-7.
Score: 0.312
-
Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma. Cancer Gene Ther. 2001 May; 8(5):378-87.
Score: 0.169
-
Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. Hum Gene Ther. 2001 Apr 10; 12(6):659-70.
Score: 0.169
-
Nonlethal detection of transgene expression in the CNS of founder mice. Biotechniques. 1999 Feb; 26(2):302-4, 306-7.
Score: 0.145
-
Antitumor responses induced by transgenic expression of CD40 ligand. Hum Gene Ther. 1997 Nov 01; 8(16):1935-43.
Score: 0.133
-
Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies. Cancer Immunol Res. 2018 01; 6(1):47-58.
Score: 0.133
-
Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung Cancers. Mol Ther. 2015 Sep; 23(9):1497-506.
Score: 0.113
-
An Inducible Caspase-9 Suicide Gene to Improve the Safety of Therapy Using Human Induced Pluripotent Stem Cells. Mol Ther. 2015 Sep; 23(9):1475-85.
Score: 0.112
-
iCaspase 9 Suicide Gene System. Methods Mol Biol. 2015; 1317:87-105.
Score: 0.109
-
Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood. 2014 Jun 19; 123(25):3895-905.
Score: 0.104
-
T cell receptors and cancer: gain gives pain. Nat Med. 2010 May; 16(5):520-1.
Score: 0.079
-
The eyes have it. Mol Ther. 2010 Mar; 18(3):451-2.
Score: 0.078
-
Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther. 2004 Jul; 10(1):5-18.
Score: 0.053
-
hGFAP-cre transgenic mice for manipulation of glial and neuronal function in vivo. Genesis. 2001 Oct; 31(2):85-94.
Score: 0.044
-
"The end of the beginning": molecular and cellular biology of gene therapy keystone. 14-20 January 1999. Biochim Biophys Acta. 1999 Jul 29; 1424(1):R5-9.
Score: 0.037
-
A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia. Clin Cancer Res. 2018 12 15; 24(24):6185-6194.
Score: 0.035
-
Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape. J Clin Invest. 2016 08 01; 126(8):3036-52.
Score: 0.030
-
Clonal Dynamics In Vivo of Virus Integration Sites of T Cells Expressing a Safety Switch. Mol Ther. 2016 04; 24(4):736-45.
Score: 0.029
-
Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther. 2014 Jun; 22(6):1211-1220.
Score: 0.026
-
Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother. 2010 Oct; 33(8):780-8.
Score: 0.020
-
Engineering human tumor-specific cytotoxic T cells to function in a hypoxic environment. Mol Ther. 2008 Mar; 16(3):599-606.
Score: 0.017
-
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. 2007 Oct 15; 110(8):2793-802.
Score: 0.016